Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 7/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 7/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | PHGDH | O43175 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5751904 | 0.84 | CYP1A2 (0.47) | KCNK3KCNK9MEN1KMT2ASLC6A7 | |
| SCHEMBL5751693 | 0.83 | CYP1A2 (0.46) | KCNK3KCNK9MEN1KMT2ACYP1A2 | |
| SCHEMBL31091138 | 0.80 | SMN1; SMN2 (0.46) | KCNK3KCNK9MEN1KMT2ASLC6A7 | |
| SCHEMBL21715166 | 0.80 | SMN1; SMN2 (0.46) | KCNK3KCNK9MEN1KMT2ASLC6A7 | |
| SCHEMBL5750395 | 0.79 | SMN1; SMN2 (0.50) | KCNK3KCNK9MEN1KMT2ACYP1A2 | |
| SCHEMBL22768015 | 0.78 | CYP1A2 (0.56) | MEN1KMT2ACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1379079 | 0.77 | SMO (0.48) | SMOMEN1KMT2ASLC6A7ALDH1A1 | |
| SCHEMBL1381842 | 0.76 | SMO (0.48) | SMOSLC6A7ALDH1A1NOTUMCHRM4 | |
| SCHEMBL1381981 | 0.76 | SMO (0.48) | SMOMEN1KMT2ASLC6A7ALDH1A1 | |
| SCHEMBL6496505 | 0.75 | SMO (0.49) | SMOSLC6A7NOTUMCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651602-A2 | ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009947-A2 | ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS COMPRISING THE SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020593-A1 | Aryl-heteroaromatic compounds, compositions comprising them and use | AVENTIS PHARMA (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020593-A1 | Aryl-heteroaromatic compounds, compositions comprising them and use | TUBB3, TUBB, TUBB1 | SMO 3703/4885KCNK3 3993/4885KCNK9 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.